{"id":689114,"date":"2022-09-27T07:42:38","date_gmt":"2022-09-27T11:42:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"modified":"2022-09-27T07:42:38","modified_gmt":"2022-09-27T11:42:38","slug":"dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","title":{"rendered":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Sept.  27, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ok08jVq8tRkL4zchEY54WNKbDEsggWnEKDffHLFEmQHlupNB6gFNM4pfX2afIR7zHDDfpQ9ec0MvfzUxgkUftmOfM27t1ZHx-ZnZCGzD2g8=\" rel=\"nofollow noopener\" target=\"_blank\">Dyne Therapeutics, Inc<\/a>. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan\u2019s 6<sup>th<\/sup> Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.<\/p>\n<p>A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RFT6fEn3SQsvguGiIZg_P4qDiDt3ZbineN6hPVnvVDCWRDAhZDBJXr9CJIkeS1pEGY3P4xg6609FIrrxnWx-uhbiP-Mvs44cZwDxDVYh4bbgC-ppaY1IXr4jGW3WP1t814ys8lJWphHafOTTlBB8dVwjuENCIaKprvdE3Qc_ZAGrbXQDCazqhaiJZzWsA4w83NR2dIXKUEP5QQUxl2XCkGEi6V5Vf1h7F1XapXw5g4w=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a> and a replay will be accessible for 90 days following the presentation.<\/p>\n<p>\n        <strong>About Dyne Therapeutics<\/strong>\n      <\/p>\n<p>Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.\u00a0With its proprietary FORCE\u2122 platform, Dyne is developing modern oligonucleotide therapeutics that are designed to\u00a0overcome limitations in delivery to muscle tissue seen with other approaches.\u00a0Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic\u00a0dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RFT6fEn3SQsvguGiIZg_P3ZXA0dC2gFG6GWtR6h7V5AGcoBMxhjiWRM09oVO1sZQebgCfyK6JYMngXJO41jLfu5H9kB3-IPfEZZnokNOrrs=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.dyne-tx.com\/<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wrxlo5CHN4Skof2vAfGiMUrTQYbd6B-SipukIt2PQRuJ4VpsKmhSTtQeyU-ulUm53nvnwKrbIeHqUwsn-aJFgA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tgeT5sxTc5bBHAmI56CFZr8hmXQY8879Fwuk4jv-Rfgd3jr3w5XcoaNxyhM2jXNB4jgJH97h9WH90AeTg_tb6WetWTDizEuFE8iXHtfiKzw=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QYOuMOM0aiG2kzjml-gPYK8HFM6Nrp-b1Aa5-dZH99LQFz9GUFrPzz5Aej41nrLIyI2cm3hXCwk4h0yvEuvxsD4tlZbxhEcJHOgQL0yJHaw=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Dyne Therapeutics<br \/>Amy Reilly<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EzcL69wGMEFdztx9VUaE8tHBcUhkTF8raKxms2vHE95PoVxJFJIciSiEjcQ2DepQvM90gWrPGiYU39ZjNquP7OvX81EobHwb1y7ZbqQizCg=\" rel=\"nofollow noopener\" target=\"_blank\">areilly@dyne-tx.com<\/a><br \/>857-341-1203<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTk4YzNjYjktYWM2OS00YzI2LTk2YTMtMTBiNjM4ZWM4OTU1LTEyMTI0NDU=\/tiny\/Dyne-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.\u00a0With its proprietary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689114","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.\u00a0With its proprietary &hellip; Continue reading &quot;Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T11:42:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\",\"datePublished\":\"2022-09-27T11:42:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"wordCount\":211,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"name\":\"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\",\"datePublished\":\"2022-09-27T11:42:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.\u00a0With its proprietary &hellip; Continue reading \"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-27T11:42:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference","datePublished":"2022-09-27T11:42:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"},"wordCount":211,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/","name":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=","datePublished":"2022-09-27T11:42:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MzMxNyM1MTcxNjg2IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Present at Chardan\u2019s 6th Annual Genetic Medicines Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689114"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689114\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}